Evolent Health, Inc. — Q1 2024 Form 10-Q
Business context and reporting period
For the three months ended March 31, 2024, Evolent provided specialty care management, total cost of care management, health plan operations, and claims-processing services to health plans and other payers. Its business includes performance-based and risk-bearing arrangements. Results are consolidated through Evolent Health LLC.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $639.7 million | $427.7 million |
| Cost of revenue | $535.5 million; 83.7% of revenue | $310.5 million; 72.6% of revenue |
| Operating loss | $13.4 million | $10.4 million |
| Net loss attributable to common shareholders | $25.2 million; $0.22 per share | $26.3 million; $0.24 per share |
| Operating cash flow | $4.9 million | $(8.0) million |
Revenue increased 49.6%, while cost of revenue rose 72.5%; cost of revenue therefore consumed a larger share of sales. The filing attributes much of this mix-related margin pressure to rapid growth in the lower-gross-margin Performance Suite. SG&A declined 11.8% to $79.1 million, or 12.4% of revenue, partly reflecting lower bad-debt, lease, and legal expenses. Depreciation and amortization was $29.5 million; stock-based compensation was $18.8 million.
The common-shareholder net loss narrowed year over year, but the comparison includes a substantial prior-year tax benefit and gain from the change in the tax receivables agreement liability. Q1 2024 had a $0.6 million income tax expense; Q1 2023 had a $68.2 million tax benefit and a $66.2 million benefit from the TRA liability change.
At March 31, 2024, cash and cash equivalents were $165.1 million and restricted cash and investments were $68.3 million. Management stated that liquidity was sufficient for at least the next 12 months. Restricted amounts include $49.8 million held for partners’ claims processing and are not all freely available. Long-term debt, net, was $597.9 million. Face-value debt included $575.0 million of convertible notes and $37.5 million outstanding under a secured revolving facility. Series A preferred stock carries floating-rate cash dividends.
Material changes versus the prior comparable period
- Revenue rose $212.0 million, mainly from expanded services for existing partners, a full quarter of NIA, and $18.1 million of Medicare shared-savings gainshare revenue versus $3.7 million a year earlier. Administrative services revenue declined $24.5 million.
- Cost of revenue increased $225.1 million, including higher claims costs associated with acquisitions and customers moving from administrative-services-only to risk-based contracts. The company also cited new Performance Suite contract start-up timing, reduced claims visibility following the Change Healthcare cyberattack, elevated authorizations, and specialty-service costs.
- Operating cash flow improved from an outflow of $8.0 million to an inflow of $4.9 million, with working-capital timing and claims-related payments materially affecting the period.
- Interest expense fell to $6.0 million from $12.9 million, mainly following repayment of term-loan debt, partly offset by interest on the 2029 Notes.
Outlook, risks, contingencies, and unusual items
- No specific full-year revenue, earnings, or cash-flow guidance is provided in the filing. Management expects the 2023 repositioning plan to be substantially complete by the end of Q2 2024; estimated total charges are $48.8 million, of which $45.2 million had been incurred by March 31.
- The company paid the $88.7 million NIA earnout in April 2024. It also paid $6.75 million in lease termination amounts on April 1, 2024, including the final installments described in the filing.
- Management expects interest expense to decline following repayment of floating-rate term debt and says it is focused on long-term deleveraging. The remaining $37.5 million revolving balance and Series A preferred dividends are exposed to SOFR changes; a 1% SOFR increase would add about $0.4 million annual interest expense and $1.8 million annual preferred dividends.
- Revenue and receivables are concentrated among a small number of partners. Humana represented 21.6% of Q1 revenue; Cook County represented 43.3% of short-term trade receivables. Loss or renegotiation of a major partner relationship could materially affect results.
- Claims reserves depend on estimates, including completion factors and medical-cost trends. The Change Healthcare cyberattack reduced visibility into claims reserves during the quarter. Reserve changes can affect current-period results.
- A shareholder demand concerning the former Passport relationship was rejected by the Board in February 2024; the company cannot estimate a potential loss or range. The filing also identifies risks from healthcare regulation, cyber and service disruptions, acquisitions, debt, and goodwill or intangible-asset impairment. No goodwill impairment trigger was identified in Q1.
Important facts for investors to verify
- Whether Performance Suite growth can be delivered without continued pressure on cost of revenue and margins.
- Whether claims costs and reserves normalize as new risk contracts mature and claims data visibility improves.
- Cash available after the NIA earnout and lease payments, including the amount of restricted cash that is unavailable for general use.
- Debt service, preferred dividend obligations, and progress toward management’s stated deleveraging objective.
- Partner retention, revenue concentration, and the sustainability of shared-savings and gainshare revenue.
- Execution and remaining costs of the repositioning plan, and any material developments in the Passport-related matter.